Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties
29 Janeiro 2024 - 9:00AM
Business Wire
Liability for future sales to be determined
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA
testing, today announced that a jury in the U.S. District Court for
the District of Delaware has reached a unanimous verdict in favor
of Natera in its patent infringement case against CareDx, Inc.
The jury awarded Natera $83.7 million in lost profits and $12.6
million in past royalties after finding that the accused CareDx
products, AlloSure and AlloSeq, infringe one of the two Natera
patents asserted against CareDx, and that all asserted claims of
both patents are valid on various grounds. The jury also provided
an advisory verdict to the judge that all asserted claims of both
patents are valid under 35 U.S.C. Sec. 101. A schedule will be set
for further proceedings to determine whether CareDx’s future sales
of new versions of AlloSeq and AlloSure also infringe the asserted
Natera patents.
Previously, Natera successfully invalidated all three of
CareDx’s patents that were asserted by CareDx against Natera in a
separate lawsuit. The invalidity of CareDx’s patents was affirmed
on appeal.
The Company stated: “We are pleased with the jury’s verdict and
will continue to deliver innovations backed by rigorous science to
improve care for transplant patients.”
Natera has more than 400 issued or pending patents across organ
health, oncology and women’s health.
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated
to oncology, women’s health, and organ health. We aim to make
personalized genetic testing and diagnostics part of the standard
of care to protect health, and inform earlier, more targeted
interventions that help lead to longer, healthier lives. Natera’s
tests are validated by more than 180 peer-reviewed publications
that demonstrate high accuracy. Natera operates ISO 13485-certified
and CAP-accredited laboratories certified under the Clinical
Laboratory Improvement Amendments (CLIA) in Austin, Texas and San
Carlos, California. For more information, visit www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts
contained in this press release are forward-looking statements and
are not a representation that Natera’s plans, estimates, or
expectations will be achieved. These forward-looking statements
represent Natera’s expectations as of the date of this press
release, and Natera disclaims any obligation to update the
forward-looking statements. These forward-looking statements are
subject to known and unknown risks and uncertainties that may cause
actual results to differ materially, including with respect to
developments in matters under dispute or litigation, the scope of
protection we establish and maintain for, and developments or
disputes concerning, our intellectual property or other proprietary
rights, and our expectations of the benefits of our tests and
product offerings to patients, providers and payers. Additional
risks and uncertainties are discussed in greater detail in “Risk
Factors” in Natera’s recent filings on Forms 10-K and 10-Q and in
other filings Natera makes with the SEC from time to time. These
documents are available at www.natera.com/investors and
www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240129057731/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc.,
510-826-2350, investor@natera.com Media: Lesley Bogdanow, VP of
Corporate Communications, Natera, Inc., pr@natera.com
Natera (NASDAQ:NTRA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Natera (NASDAQ:NTRA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024